在遗传性和偶发性帕金森病小鼠中,SYNJ1通过调节TSP-1表达的上升来挽救运动功能
Yueqin Tian1, Shang Yi1, Wanyun Guo2
1Department of Neurology, Zhujiang Hospital, Southern Medical University, No. 253 Gongye Avenue, Guangzhou, Guangdong 510282, PR China.
Behavioural brain research
|July 7, 2023
概括
降低的SYNJ1水平与帕金森病 (PD) 运动缺陷有关. 抑制SYNJ1可能通过增加TSP-1提供神经保护,这表明SYNJ1是PD的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 帕金森病 (PD) 是一种神经退行性疾病,其特征是运动功能障碍和多巴胺基神经元的丧失.
- 导致PD病变的精确分子机制尚不完全理解.
- 研究新的遗传因素和途径对于开发有效的PD疗法至关重要.
研究的目的:
- 阐明Synaptojanin 1 (SYNJ1) 在帕金森病中的作用.
- 探索SYNJ1及其下游效应物的神经保护潜力.
- 确定SYNJ1作为PD的潜在治疗点.
主要方法:
- 在小鼠PD模型 (hSNCA*A53T-Tg和MPTP诱导) 与对照对SYNJ1表达的比较分析.
- 病毒载体介导的SYNJ1在小鼠条纹体中的上调,以评估功能和病理恢复.
- 转录基因测序,生物信息学,qPCR,虚拟蛋白质-蛋白质对接和共免疫沉,以识别和验证SYNJ1的下游途径和相互作用.
主要成果:
- 在PD小鼠模型的 substantiaia nigra (SN) 和条纹体中,SYNJ1表达显著下降,与运动缺陷,α-synuclein增加和氨酸氧酶减少相关.
- 条纹体中SYNJ1的升高调节挽救了PD小鼠的行为障碍和改善了病理变化.
- 在SH-SY5Y细胞中SYNJ1的淘汰导致Thrombospondin-1 (TSP-1) 表达的减少,这涉及到细胞外矩阵通路. 一个SYNJ1-TSP-1相互作用被提议和验证,尽管在老年PD小鼠中减弱.
结论:
- 降低SYNJ1与PD病理和运动功能障碍有关.
- 在PD模型中,SYNJ1的过度表达表明神经保护作用,可能通过TSP-1的上调和细胞外矩阵通路的调节.
- SYNJ1代表了帕金森病的有前途的治疗标,需要进一步的机制研究.
相关概念视频
Parkinson's Disease: Treatment
302
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
302
Parkinson's Disease: Overview
606
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
606


